- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Leading-edge research and technologies that facilitate drug discovery
This definitive compilation of information on current drug discovery research reviews?some of the most important topics in post-genomic?biomedical and biopharmaceutical science, such as pharmacogenomics, structure-based drug design, medicinal chemistry, chemical biology, cancer biology, neuroscience, bio-nanotechnology, and stem cell research.
Including a Foreword by the late Nobel laureate Paul C. Lauterbur, and with contributions from seventy scholars and researchers from around the world, this book incorporates a…mehr
Andere Kunden interessierten sich auch für
- Dev P. AryaAminoglycoside Antibiotics215,99 €
- Pharmacogenetics153,99 €
- Drug Metabolism in Drug Design and Development197,99 €
- Dimitri SemizarovGenomics Drug Discovery191,99 €
- Ana Martinez / Ana Castro / Miguel Medina (eds.)Glycogen Synthase Kinase 3 (Gsk-3) and Its Inhibitors215,99 €
- Luis M BotanaTherapeutic Targets202,99 €
- Mass Spectrometry in Drug Metabolism and Pharmacokinetics158,99 €
-
-
-
Leading-edge research and technologies that facilitate drug discovery
This definitive compilation of information on current drug discovery research reviews?some of the most important topics in post-genomic?biomedical and biopharmaceutical science, such as pharmacogenomics, structure-based drug design, medicinal chemistry, chemical biology, cancer biology, neuroscience, bio-nanotechnology, and stem cell research.
Including a Foreword by the late Nobel laureate Paul C. Lauterbur, and with contributions from seventy scholars and researchers from around the world, this book incorporates a general introduction to and practical examples of some of the many methods and techniques for the research of biopharmaceutical discovery in the post-genomic era. The contributors include experts in chemistry, structural biology, computation, biology, and medicine who have a common interest in translating research discoveries into new human therapies. In addition to exploring recent advances, they share their perspectives on various aspects of drug discovery research in the future.
Drug Discovery Research: New Frontiers in the Post-Genomic Era is a hands-on resource for practitioners and researchers in the pharmaceutical field and related industries, as well as a valuable reference for students in pharmaceutical science, chemistry, biology, biophysics, bioengineering, pharmacy, and medicine.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
This definitive compilation of information on current drug discovery research reviews?some of the most important topics in post-genomic?biomedical and biopharmaceutical science, such as pharmacogenomics, structure-based drug design, medicinal chemistry, chemical biology, cancer biology, neuroscience, bio-nanotechnology, and stem cell research.
Including a Foreword by the late Nobel laureate Paul C. Lauterbur, and with contributions from seventy scholars and researchers from around the world, this book incorporates a general introduction to and practical examples of some of the many methods and techniques for the research of biopharmaceutical discovery in the post-genomic era. The contributors include experts in chemistry, structural biology, computation, biology, and medicine who have a common interest in translating research discoveries into new human therapies. In addition to exploring recent advances, they share their perspectives on various aspects of drug discovery research in the future.
Drug Discovery Research: New Frontiers in the Post-Genomic Era is a hands-on resource for practitioners and researchers in the pharmaceutical field and related industries, as well as a valuable reference for students in pharmaceutical science, chemistry, biology, biophysics, bioengineering, pharmacy, and medicine.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Wiley & Sons
- 1. Auflage
- Seitenzahl: 552
- Erscheinungstermin: 1. Juli 2007
- Englisch
- Abmessung: 235mm x 167mm x 33mm
- Gewicht: 935g
- ISBN-13: 9780471672005
- ISBN-10: 0471672009
- Artikelnr.: 22582716
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
- Verlag: Wiley & Sons
- 1. Auflage
- Seitenzahl: 552
- Erscheinungstermin: 1. Juli 2007
- Englisch
- Abmessung: 235mm x 167mm x 33mm
- Gewicht: 935g
- ISBN-13: 9780471672005
- ISBN-10: 0471672009
- Artikelnr.: 22582716
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
Ziwei Huang, PHD, is Professor at the Burnham Institute for Medical Research and Adjunct Professor at the University of California at San Diego. He was previously Assistant Professor at Thomas Jefferson University in Philadelphia (1995-2000) and tenured Associate Professor at the University of Illinois at Urbana-Champaign (2000-2004). The author or coauthor of numerous publications and patents, Professor Huang has conducted research in cross-disciplinary areas related to drug discovery, medicinal chemistry, biochemistry, and chemical biology and has developed novel therapeutic agents and research probes for treating or studying human diseases. He has organized many international conferences and workshops in drug discovery research in America and Asia. Additionally, Professor Huang has had close interaction with the biotechnology and pharmaceutical industries as the founder of several biopharmaceutical companies and consultant for many major biotechnology and pharmaceutical companies.
FOREWORD. INTRODUCTION. CONTRIBUTORS. PART I. COMPUTATIONAL AND STRUCTURAL APPROACHES IN DRUG DISCOVERY. CHAPTER 1. MOLECULAR DOCKING AND STRUCTURE-BASED DESIGN (P. Therese Lang
University of California
San Francisco
CA; Tiba Aynechi
University of California
San Francisco
CA; Demetri Moustakas
University of California
Berkeley
CA; Brian Shoichet
Irwin D. Kuntz
* University of California
San Francisco
CA; Natasja Brooijmans
University of California
San Francisco
CA; and Connie M. Oshiro
Roche
Palo Alto
CA). CHAPTER 2. RECENT ADVANCES IN DRUG DISCOVERY RESEARCH USING STRUCTURE-BASED VIRTUAL SCREENING TECHNIQUES: EXAMPLES OF SUCCESS FOR DIVERSE PROTEIN TARGETS (Sutapa Ghosh (Burnham Institute for Medical Research La Jolla
CA)
Aihua Nie (Burnham Institute for Medical Research La Jolla
CA)
Jing An (Burnham Institute for Medical Research La Jolla
CA)
and Ziwei Huang* (University of California
San Diego; Burnham Institute for Medical Research La Jolla
CA). CHAPTER 3. VIRTUAL SCREENING IN DRUG DISCOVERY (Malcolm J. McGregor
Zhaowen Luo
and Xuliang Jiang* (Serono Research Institute
Rockland
MA). CHAPTER 4. COMPUTER-AIDED DRUG DESIGN (Grace Shiahuy Chen
Providence University
Shalu
Taiwan
Republic of China and Ji-Wang Chern
* National Taiwan University
Taipei
Taiwan
Republic of China). CHAPTER 5. FOCUSED LIBRARY DESIGN BASED ON HIT AND TARGET STRUCTURES: METHOD AND APPLICATION IN DRUG DISCOVERY (Weiliang Zhu (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
Jian Li (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
Zhen Gong (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
Hong Liu (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
and Hualiang Jiang* (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China
East China University of Science and Technology
Shanghai
P.R. China). PART II. CHEMICAL AND SYNTHETIC APPROACHES IN DRUG DISCOVERY. CHAPTER 6. BEYOND NATURAL PRODUCTS: SYNTHETIC ANALOGUES OF BRYOSTATIN 1 (Paul A. Wender*
Jeremy L. Baryza
Michael K. Hilinski
Joshua C. Horan
Cindy Kan
and Vishal A. Verma (Stanford University
Stanford
CA). CHAPTER 7. THE PROMISES AND PITFALLS OF SMALL-MOLECULE INHIBITION OF POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) (Amanda C. Nottbohm and Paul J. Hergenrother* (University of Illinois at Urbana-Champaign
Urbana
IL). CHAPTER 8. CYCLIC ADP-RIBOSE ANALOGUES WITH MINIMAL STRUCTURE: SYNTHESIS AND CALCIUM-RELEASE ACTIVITY (Lihe Zhang* (Peking University
Beijing
P.R. China) and Andreas H. Guse (University Hospital Hamburg-Eppendorf
Institute of Biochemistry and Molecular Biology
Hamburg
Germany). CHAPTER 9. EVALUATION OF NEUROIMMUNOPHILIN LIGANDS (Junhai Xiao
Aihua Nie
and Song Li* (Beijing Institute of Pharmacology and Toxicology
Beijing
P.R. China). CHAPTER 10. CHIRAL DRUGS AND THE ASSOCIATED ASYMMETRIC SYNTHESIS (Jiange Zhang (Zhengzhou University
Zhengzhou
P.R. China) and Guoqiang Lin* (Shanghai Institute of Organic Chemistry
Chinese Academy of Sciences
Shanghai
P.R. China). CHAPTER 11. ALPHA-HELIX MIMETICS IN DRUG DISCOVERY 281 Hang Yin
Gui-In Lee
and Andrew D. Hamilton* Yale University
New Haven
CT CHAPTER 12. BASIC AND TRANSLATIONAL RESEARCH OF CHEMOKINE LIGANDS AND RECEPTORS AND DEVELOPMENT OF NOVEL THERAPEUTICS (Won-Tak Choi
University of Illinois at Urbana-Champaign
Urbana
IL; Yohichi Kumaki
Raylight Corporation
Chemokine Pharmaceutical Inc.
La Jolla
CA; I. M. Krishna Kumar
Burnham Institute for Medical Research
La Jolla
CA; Jing An
Burnham Institute for Medical Research
La Jolla
CA; Douglas D. Richman
Department of Molecular Pathology
University of California
San Diego
CA; Joseph G. Sodroski
Dana-Farber Cancer Institute
Harvard Medical School
Boston
MA; and Ziwei Huang
* University of Illinois at Urbana-Champaign
Urbana
IL
Burnham Institute for Medical Research
La Jolla
CA; Department of Molecular Pathology
University of California
San Diego
CA). CHAPTER 13. RESEARCH PROGRESS IN PROTEIN POST-TRANSLATIONAL MODIFICATION (Jia Hu
Yanting Guo
and Yanmei Li
* Tsinghua University
Beijing
P.R. China). CHAPTER 14. CONTROLLED RELEASE OFANTIBIOTICS ENCAPSULATED IN NANOPOROUS SOL-GEL MATERIALS WITH TUNABLE PORE PARAMETERS (Houping Yin
Laura Zheng
and Yen Wei
* Drexel University
Philadelphia
PA). PART III. BIOLOGICAL APPROACHES AND TRANSLATIONAL RESEARCH IN DRUG DISCOVERY. CHAPTER 15. RETINOIC ACID AND ARSENIC TRIOXIDE TREATMENT IN ACUTE PROMYELOCYTIC LEUKEMIA: A MODEL OF ONCOPROTEIN TARGETED THERAPY (Jian-Hua Tong
Sai-Juan Chen
and Zhu Chen
* Shanghai Institute of Hematology
Rui Jin Hospital
School of Medicine
Shanghai Jiao Tong University
Shanghai
P.R. China). CHAPTER 16. 2-CHLORODEOXYADENOSINE (CLADRIBINE): RATIONAL DEVELOPMENT OFA NOVEL CHEMOTHERAPEUTIC AGENT (Howard B. Cottam and Dennis A. Carson
* Moores Cancer Center
University of California
San Diego
CA). CHAPTER 17. APOPTOSIS-BASED DRUG DISCOVERY FOR CANCER (John C. Reed*
Dayong Zhai
Marc Hyer
and Kate Welsh
Burnham Institute for Medical Research
La Jolla
CA). CHAPTER 18. MECHANISM-BASED DEVELOPMENT OF MEMANTINE AS A THERAPEUTIC AGENT IN TREATING ALZHEIMER'S DISEASE AND OTHER NEUROLOGIC DISORDERS: LOW-AFFINITY
UNCOMPETITIVE ANTAGONISM WITH FAST OFF-RATE (Huei-Sheng Vincent Chen*
and Stuart A. Lipton
* Burnham Institute for Medical Research
La Jolla
CA; University of California
San Diego
CA). CHAPTER 19. BRIDGING BENCH TO CLINIC: ROLES OFANIMAL MODELS FOR POST-GENOMICS DRUG DISCOVERY ON METABOLIC DISEASES (Chi-Wai Wong and Ling Chen
* Guangzhou Institute of Biomedicine and Health
Chinese Academy of Sciences
Guangzhou
P.R. China). CHAPTER 20. STEM CELL RESEARCH AND APPLICATIONS FOR HUMAN THERAPIES (Prithi Rajan
Kook In Park
Vaclav Ourednik
Jean Pyo Lee
Jamie Imitola
Franz-Joseph Mueller
Yang D. Teng
and Evan Snyder
* Burnham Institute for Medical Research
La Jolla
CA). INDEX.
University of California
San Francisco
CA; Tiba Aynechi
University of California
San Francisco
CA; Demetri Moustakas
University of California
Berkeley
CA; Brian Shoichet
Irwin D. Kuntz
* University of California
San Francisco
CA; Natasja Brooijmans
University of California
San Francisco
CA; and Connie M. Oshiro
Roche
Palo Alto
CA). CHAPTER 2. RECENT ADVANCES IN DRUG DISCOVERY RESEARCH USING STRUCTURE-BASED VIRTUAL SCREENING TECHNIQUES: EXAMPLES OF SUCCESS FOR DIVERSE PROTEIN TARGETS (Sutapa Ghosh (Burnham Institute for Medical Research La Jolla
CA)
Aihua Nie (Burnham Institute for Medical Research La Jolla
CA)
Jing An (Burnham Institute for Medical Research La Jolla
CA)
and Ziwei Huang* (University of California
San Diego; Burnham Institute for Medical Research La Jolla
CA). CHAPTER 3. VIRTUAL SCREENING IN DRUG DISCOVERY (Malcolm J. McGregor
Zhaowen Luo
and Xuliang Jiang* (Serono Research Institute
Rockland
MA). CHAPTER 4. COMPUTER-AIDED DRUG DESIGN (Grace Shiahuy Chen
Providence University
Shalu
Taiwan
Republic of China and Ji-Wang Chern
* National Taiwan University
Taipei
Taiwan
Republic of China). CHAPTER 5. FOCUSED LIBRARY DESIGN BASED ON HIT AND TARGET STRUCTURES: METHOD AND APPLICATION IN DRUG DISCOVERY (Weiliang Zhu (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
Jian Li (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
Zhen Gong (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
Hong Liu (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
and Hualiang Jiang* (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China
East China University of Science and Technology
Shanghai
P.R. China). PART II. CHEMICAL AND SYNTHETIC APPROACHES IN DRUG DISCOVERY. CHAPTER 6. BEYOND NATURAL PRODUCTS: SYNTHETIC ANALOGUES OF BRYOSTATIN 1 (Paul A. Wender*
Jeremy L. Baryza
Michael K. Hilinski
Joshua C. Horan
Cindy Kan
and Vishal A. Verma (Stanford University
Stanford
CA). CHAPTER 7. THE PROMISES AND PITFALLS OF SMALL-MOLECULE INHIBITION OF POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) (Amanda C. Nottbohm and Paul J. Hergenrother* (University of Illinois at Urbana-Champaign
Urbana
IL). CHAPTER 8. CYCLIC ADP-RIBOSE ANALOGUES WITH MINIMAL STRUCTURE: SYNTHESIS AND CALCIUM-RELEASE ACTIVITY (Lihe Zhang* (Peking University
Beijing
P.R. China) and Andreas H. Guse (University Hospital Hamburg-Eppendorf
Institute of Biochemistry and Molecular Biology
Hamburg
Germany). CHAPTER 9. EVALUATION OF NEUROIMMUNOPHILIN LIGANDS (Junhai Xiao
Aihua Nie
and Song Li* (Beijing Institute of Pharmacology and Toxicology
Beijing
P.R. China). CHAPTER 10. CHIRAL DRUGS AND THE ASSOCIATED ASYMMETRIC SYNTHESIS (Jiange Zhang (Zhengzhou University
Zhengzhou
P.R. China) and Guoqiang Lin* (Shanghai Institute of Organic Chemistry
Chinese Academy of Sciences
Shanghai
P.R. China). CHAPTER 11. ALPHA-HELIX MIMETICS IN DRUG DISCOVERY 281 Hang Yin
Gui-In Lee
and Andrew D. Hamilton* Yale University
New Haven
CT CHAPTER 12. BASIC AND TRANSLATIONAL RESEARCH OF CHEMOKINE LIGANDS AND RECEPTORS AND DEVELOPMENT OF NOVEL THERAPEUTICS (Won-Tak Choi
University of Illinois at Urbana-Champaign
Urbana
IL; Yohichi Kumaki
Raylight Corporation
Chemokine Pharmaceutical Inc.
La Jolla
CA; I. M. Krishna Kumar
Burnham Institute for Medical Research
La Jolla
CA; Jing An
Burnham Institute for Medical Research
La Jolla
CA; Douglas D. Richman
Department of Molecular Pathology
University of California
San Diego
CA; Joseph G. Sodroski
Dana-Farber Cancer Institute
Harvard Medical School
Boston
MA; and Ziwei Huang
* University of Illinois at Urbana-Champaign
Urbana
IL
Burnham Institute for Medical Research
La Jolla
CA; Department of Molecular Pathology
University of California
San Diego
CA). CHAPTER 13. RESEARCH PROGRESS IN PROTEIN POST-TRANSLATIONAL MODIFICATION (Jia Hu
Yanting Guo
and Yanmei Li
* Tsinghua University
Beijing
P.R. China). CHAPTER 14. CONTROLLED RELEASE OFANTIBIOTICS ENCAPSULATED IN NANOPOROUS SOL-GEL MATERIALS WITH TUNABLE PORE PARAMETERS (Houping Yin
Laura Zheng
and Yen Wei
* Drexel University
Philadelphia
PA). PART III. BIOLOGICAL APPROACHES AND TRANSLATIONAL RESEARCH IN DRUG DISCOVERY. CHAPTER 15. RETINOIC ACID AND ARSENIC TRIOXIDE TREATMENT IN ACUTE PROMYELOCYTIC LEUKEMIA: A MODEL OF ONCOPROTEIN TARGETED THERAPY (Jian-Hua Tong
Sai-Juan Chen
and Zhu Chen
* Shanghai Institute of Hematology
Rui Jin Hospital
School of Medicine
Shanghai Jiao Tong University
Shanghai
P.R. China). CHAPTER 16. 2-CHLORODEOXYADENOSINE (CLADRIBINE): RATIONAL DEVELOPMENT OFA NOVEL CHEMOTHERAPEUTIC AGENT (Howard B. Cottam and Dennis A. Carson
* Moores Cancer Center
University of California
San Diego
CA). CHAPTER 17. APOPTOSIS-BASED DRUG DISCOVERY FOR CANCER (John C. Reed*
Dayong Zhai
Marc Hyer
and Kate Welsh
Burnham Institute for Medical Research
La Jolla
CA). CHAPTER 18. MECHANISM-BASED DEVELOPMENT OF MEMANTINE AS A THERAPEUTIC AGENT IN TREATING ALZHEIMER'S DISEASE AND OTHER NEUROLOGIC DISORDERS: LOW-AFFINITY
UNCOMPETITIVE ANTAGONISM WITH FAST OFF-RATE (Huei-Sheng Vincent Chen*
and Stuart A. Lipton
* Burnham Institute for Medical Research
La Jolla
CA; University of California
San Diego
CA). CHAPTER 19. BRIDGING BENCH TO CLINIC: ROLES OFANIMAL MODELS FOR POST-GENOMICS DRUG DISCOVERY ON METABOLIC DISEASES (Chi-Wai Wong and Ling Chen
* Guangzhou Institute of Biomedicine and Health
Chinese Academy of Sciences
Guangzhou
P.R. China). CHAPTER 20. STEM CELL RESEARCH AND APPLICATIONS FOR HUMAN THERAPIES (Prithi Rajan
Kook In Park
Vaclav Ourednik
Jean Pyo Lee
Jamie Imitola
Franz-Joseph Mueller
Yang D. Teng
and Evan Snyder
* Burnham Institute for Medical Research
La Jolla
CA). INDEX.
FOREWORD. INTRODUCTION. CONTRIBUTORS. PART I. COMPUTATIONAL AND STRUCTURAL APPROACHES IN DRUG DISCOVERY. CHAPTER 1. MOLECULAR DOCKING AND STRUCTURE-BASED DESIGN (P. Therese Lang
University of California
San Francisco
CA; Tiba Aynechi
University of California
San Francisco
CA; Demetri Moustakas
University of California
Berkeley
CA; Brian Shoichet
Irwin D. Kuntz
* University of California
San Francisco
CA; Natasja Brooijmans
University of California
San Francisco
CA; and Connie M. Oshiro
Roche
Palo Alto
CA). CHAPTER 2. RECENT ADVANCES IN DRUG DISCOVERY RESEARCH USING STRUCTURE-BASED VIRTUAL SCREENING TECHNIQUES: EXAMPLES OF SUCCESS FOR DIVERSE PROTEIN TARGETS (Sutapa Ghosh (Burnham Institute for Medical Research La Jolla
CA)
Aihua Nie (Burnham Institute for Medical Research La Jolla
CA)
Jing An (Burnham Institute for Medical Research La Jolla
CA)
and Ziwei Huang* (University of California
San Diego; Burnham Institute for Medical Research La Jolla
CA). CHAPTER 3. VIRTUAL SCREENING IN DRUG DISCOVERY (Malcolm J. McGregor
Zhaowen Luo
and Xuliang Jiang* (Serono Research Institute
Rockland
MA). CHAPTER 4. COMPUTER-AIDED DRUG DESIGN (Grace Shiahuy Chen
Providence University
Shalu
Taiwan
Republic of China and Ji-Wang Chern
* National Taiwan University
Taipei
Taiwan
Republic of China). CHAPTER 5. FOCUSED LIBRARY DESIGN BASED ON HIT AND TARGET STRUCTURES: METHOD AND APPLICATION IN DRUG DISCOVERY (Weiliang Zhu (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
Jian Li (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
Zhen Gong (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
Hong Liu (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
and Hualiang Jiang* (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China
East China University of Science and Technology
Shanghai
P.R. China). PART II. CHEMICAL AND SYNTHETIC APPROACHES IN DRUG DISCOVERY. CHAPTER 6. BEYOND NATURAL PRODUCTS: SYNTHETIC ANALOGUES OF BRYOSTATIN 1 (Paul A. Wender*
Jeremy L. Baryza
Michael K. Hilinski
Joshua C. Horan
Cindy Kan
and Vishal A. Verma (Stanford University
Stanford
CA). CHAPTER 7. THE PROMISES AND PITFALLS OF SMALL-MOLECULE INHIBITION OF POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) (Amanda C. Nottbohm and Paul J. Hergenrother* (University of Illinois at Urbana-Champaign
Urbana
IL). CHAPTER 8. CYCLIC ADP-RIBOSE ANALOGUES WITH MINIMAL STRUCTURE: SYNTHESIS AND CALCIUM-RELEASE ACTIVITY (Lihe Zhang* (Peking University
Beijing
P.R. China) and Andreas H. Guse (University Hospital Hamburg-Eppendorf
Institute of Biochemistry and Molecular Biology
Hamburg
Germany). CHAPTER 9. EVALUATION OF NEUROIMMUNOPHILIN LIGANDS (Junhai Xiao
Aihua Nie
and Song Li* (Beijing Institute of Pharmacology and Toxicology
Beijing
P.R. China). CHAPTER 10. CHIRAL DRUGS AND THE ASSOCIATED ASYMMETRIC SYNTHESIS (Jiange Zhang (Zhengzhou University
Zhengzhou
P.R. China) and Guoqiang Lin* (Shanghai Institute of Organic Chemistry
Chinese Academy of Sciences
Shanghai
P.R. China). CHAPTER 11. ALPHA-HELIX MIMETICS IN DRUG DISCOVERY 281 Hang Yin
Gui-In Lee
and Andrew D. Hamilton* Yale University
New Haven
CT CHAPTER 12. BASIC AND TRANSLATIONAL RESEARCH OF CHEMOKINE LIGANDS AND RECEPTORS AND DEVELOPMENT OF NOVEL THERAPEUTICS (Won-Tak Choi
University of Illinois at Urbana-Champaign
Urbana
IL; Yohichi Kumaki
Raylight Corporation
Chemokine Pharmaceutical Inc.
La Jolla
CA; I. M. Krishna Kumar
Burnham Institute for Medical Research
La Jolla
CA; Jing An
Burnham Institute for Medical Research
La Jolla
CA; Douglas D. Richman
Department of Molecular Pathology
University of California
San Diego
CA; Joseph G. Sodroski
Dana-Farber Cancer Institute
Harvard Medical School
Boston
MA; and Ziwei Huang
* University of Illinois at Urbana-Champaign
Urbana
IL
Burnham Institute for Medical Research
La Jolla
CA; Department of Molecular Pathology
University of California
San Diego
CA). CHAPTER 13. RESEARCH PROGRESS IN PROTEIN POST-TRANSLATIONAL MODIFICATION (Jia Hu
Yanting Guo
and Yanmei Li
* Tsinghua University
Beijing
P.R. China). CHAPTER 14. CONTROLLED RELEASE OFANTIBIOTICS ENCAPSULATED IN NANOPOROUS SOL-GEL MATERIALS WITH TUNABLE PORE PARAMETERS (Houping Yin
Laura Zheng
and Yen Wei
* Drexel University
Philadelphia
PA). PART III. BIOLOGICAL APPROACHES AND TRANSLATIONAL RESEARCH IN DRUG DISCOVERY. CHAPTER 15. RETINOIC ACID AND ARSENIC TRIOXIDE TREATMENT IN ACUTE PROMYELOCYTIC LEUKEMIA: A MODEL OF ONCOPROTEIN TARGETED THERAPY (Jian-Hua Tong
Sai-Juan Chen
and Zhu Chen
* Shanghai Institute of Hematology
Rui Jin Hospital
School of Medicine
Shanghai Jiao Tong University
Shanghai
P.R. China). CHAPTER 16. 2-CHLORODEOXYADENOSINE (CLADRIBINE): RATIONAL DEVELOPMENT OFA NOVEL CHEMOTHERAPEUTIC AGENT (Howard B. Cottam and Dennis A. Carson
* Moores Cancer Center
University of California
San Diego
CA). CHAPTER 17. APOPTOSIS-BASED DRUG DISCOVERY FOR CANCER (John C. Reed*
Dayong Zhai
Marc Hyer
and Kate Welsh
Burnham Institute for Medical Research
La Jolla
CA). CHAPTER 18. MECHANISM-BASED DEVELOPMENT OF MEMANTINE AS A THERAPEUTIC AGENT IN TREATING ALZHEIMER'S DISEASE AND OTHER NEUROLOGIC DISORDERS: LOW-AFFINITY
UNCOMPETITIVE ANTAGONISM WITH FAST OFF-RATE (Huei-Sheng Vincent Chen*
and Stuart A. Lipton
* Burnham Institute for Medical Research
La Jolla
CA; University of California
San Diego
CA). CHAPTER 19. BRIDGING BENCH TO CLINIC: ROLES OFANIMAL MODELS FOR POST-GENOMICS DRUG DISCOVERY ON METABOLIC DISEASES (Chi-Wai Wong and Ling Chen
* Guangzhou Institute of Biomedicine and Health
Chinese Academy of Sciences
Guangzhou
P.R. China). CHAPTER 20. STEM CELL RESEARCH AND APPLICATIONS FOR HUMAN THERAPIES (Prithi Rajan
Kook In Park
Vaclav Ourednik
Jean Pyo Lee
Jamie Imitola
Franz-Joseph Mueller
Yang D. Teng
and Evan Snyder
* Burnham Institute for Medical Research
La Jolla
CA). INDEX.
University of California
San Francisco
CA; Tiba Aynechi
University of California
San Francisco
CA; Demetri Moustakas
University of California
Berkeley
CA; Brian Shoichet
Irwin D. Kuntz
* University of California
San Francisco
CA; Natasja Brooijmans
University of California
San Francisco
CA; and Connie M. Oshiro
Roche
Palo Alto
CA). CHAPTER 2. RECENT ADVANCES IN DRUG DISCOVERY RESEARCH USING STRUCTURE-BASED VIRTUAL SCREENING TECHNIQUES: EXAMPLES OF SUCCESS FOR DIVERSE PROTEIN TARGETS (Sutapa Ghosh (Burnham Institute for Medical Research La Jolla
CA)
Aihua Nie (Burnham Institute for Medical Research La Jolla
CA)
Jing An (Burnham Institute for Medical Research La Jolla
CA)
and Ziwei Huang* (University of California
San Diego; Burnham Institute for Medical Research La Jolla
CA). CHAPTER 3. VIRTUAL SCREENING IN DRUG DISCOVERY (Malcolm J. McGregor
Zhaowen Luo
and Xuliang Jiang* (Serono Research Institute
Rockland
MA). CHAPTER 4. COMPUTER-AIDED DRUG DESIGN (Grace Shiahuy Chen
Providence University
Shalu
Taiwan
Republic of China and Ji-Wang Chern
* National Taiwan University
Taipei
Taiwan
Republic of China). CHAPTER 5. FOCUSED LIBRARY DESIGN BASED ON HIT AND TARGET STRUCTURES: METHOD AND APPLICATION IN DRUG DISCOVERY (Weiliang Zhu (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
Jian Li (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
Zhen Gong (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
Hong Liu (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China)
and Hualiang Jiang* (Shanghai Institute ofMateriaMedica
Chinese Academy of Sciences
Shanghai
P.R. China
East China University of Science and Technology
Shanghai
P.R. China). PART II. CHEMICAL AND SYNTHETIC APPROACHES IN DRUG DISCOVERY. CHAPTER 6. BEYOND NATURAL PRODUCTS: SYNTHETIC ANALOGUES OF BRYOSTATIN 1 (Paul A. Wender*
Jeremy L. Baryza
Michael K. Hilinski
Joshua C. Horan
Cindy Kan
and Vishal A. Verma (Stanford University
Stanford
CA). CHAPTER 7. THE PROMISES AND PITFALLS OF SMALL-MOLECULE INHIBITION OF POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) (Amanda C. Nottbohm and Paul J. Hergenrother* (University of Illinois at Urbana-Champaign
Urbana
IL). CHAPTER 8. CYCLIC ADP-RIBOSE ANALOGUES WITH MINIMAL STRUCTURE: SYNTHESIS AND CALCIUM-RELEASE ACTIVITY (Lihe Zhang* (Peking University
Beijing
P.R. China) and Andreas H. Guse (University Hospital Hamburg-Eppendorf
Institute of Biochemistry and Molecular Biology
Hamburg
Germany). CHAPTER 9. EVALUATION OF NEUROIMMUNOPHILIN LIGANDS (Junhai Xiao
Aihua Nie
and Song Li* (Beijing Institute of Pharmacology and Toxicology
Beijing
P.R. China). CHAPTER 10. CHIRAL DRUGS AND THE ASSOCIATED ASYMMETRIC SYNTHESIS (Jiange Zhang (Zhengzhou University
Zhengzhou
P.R. China) and Guoqiang Lin* (Shanghai Institute of Organic Chemistry
Chinese Academy of Sciences
Shanghai
P.R. China). CHAPTER 11. ALPHA-HELIX MIMETICS IN DRUG DISCOVERY 281 Hang Yin
Gui-In Lee
and Andrew D. Hamilton* Yale University
New Haven
CT CHAPTER 12. BASIC AND TRANSLATIONAL RESEARCH OF CHEMOKINE LIGANDS AND RECEPTORS AND DEVELOPMENT OF NOVEL THERAPEUTICS (Won-Tak Choi
University of Illinois at Urbana-Champaign
Urbana
IL; Yohichi Kumaki
Raylight Corporation
Chemokine Pharmaceutical Inc.
La Jolla
CA; I. M. Krishna Kumar
Burnham Institute for Medical Research
La Jolla
CA; Jing An
Burnham Institute for Medical Research
La Jolla
CA; Douglas D. Richman
Department of Molecular Pathology
University of California
San Diego
CA; Joseph G. Sodroski
Dana-Farber Cancer Institute
Harvard Medical School
Boston
MA; and Ziwei Huang
* University of Illinois at Urbana-Champaign
Urbana
IL
Burnham Institute for Medical Research
La Jolla
CA; Department of Molecular Pathology
University of California
San Diego
CA). CHAPTER 13. RESEARCH PROGRESS IN PROTEIN POST-TRANSLATIONAL MODIFICATION (Jia Hu
Yanting Guo
and Yanmei Li
* Tsinghua University
Beijing
P.R. China). CHAPTER 14. CONTROLLED RELEASE OFANTIBIOTICS ENCAPSULATED IN NANOPOROUS SOL-GEL MATERIALS WITH TUNABLE PORE PARAMETERS (Houping Yin
Laura Zheng
and Yen Wei
* Drexel University
Philadelphia
PA). PART III. BIOLOGICAL APPROACHES AND TRANSLATIONAL RESEARCH IN DRUG DISCOVERY. CHAPTER 15. RETINOIC ACID AND ARSENIC TRIOXIDE TREATMENT IN ACUTE PROMYELOCYTIC LEUKEMIA: A MODEL OF ONCOPROTEIN TARGETED THERAPY (Jian-Hua Tong
Sai-Juan Chen
and Zhu Chen
* Shanghai Institute of Hematology
Rui Jin Hospital
School of Medicine
Shanghai Jiao Tong University
Shanghai
P.R. China). CHAPTER 16. 2-CHLORODEOXYADENOSINE (CLADRIBINE): RATIONAL DEVELOPMENT OFA NOVEL CHEMOTHERAPEUTIC AGENT (Howard B. Cottam and Dennis A. Carson
* Moores Cancer Center
University of California
San Diego
CA). CHAPTER 17. APOPTOSIS-BASED DRUG DISCOVERY FOR CANCER (John C. Reed*
Dayong Zhai
Marc Hyer
and Kate Welsh
Burnham Institute for Medical Research
La Jolla
CA). CHAPTER 18. MECHANISM-BASED DEVELOPMENT OF MEMANTINE AS A THERAPEUTIC AGENT IN TREATING ALZHEIMER'S DISEASE AND OTHER NEUROLOGIC DISORDERS: LOW-AFFINITY
UNCOMPETITIVE ANTAGONISM WITH FAST OFF-RATE (Huei-Sheng Vincent Chen*
and Stuart A. Lipton
* Burnham Institute for Medical Research
La Jolla
CA; University of California
San Diego
CA). CHAPTER 19. BRIDGING BENCH TO CLINIC: ROLES OFANIMAL MODELS FOR POST-GENOMICS DRUG DISCOVERY ON METABOLIC DISEASES (Chi-Wai Wong and Ling Chen
* Guangzhou Institute of Biomedicine and Health
Chinese Academy of Sciences
Guangzhou
P.R. China). CHAPTER 20. STEM CELL RESEARCH AND APPLICATIONS FOR HUMAN THERAPIES (Prithi Rajan
Kook In Park
Vaclav Ourednik
Jean Pyo Lee
Jamie Imitola
Franz-Joseph Mueller
Yang D. Teng
and Evan Snyder
* Burnham Institute for Medical Research
La Jolla
CA). INDEX.